LAG3 and neoplasm: Furthermore, zuo, et al. (Zuo et al., 2021) reported that VV-scFv-TIGIT acted synergistically with PD-1 or LAG-3 blockade, culminating in complete tumor regression in cases where tumors exhibited limited response to either VV treatment alone or immune checkpoint blockade monotherapy.